Member Profile
TRI Cap Portfolio - Centeo
First Investment February 2009
TRI Cap has participated in a funding package totalling up to £700,000 for Dumbarton-based Centeo Biosciences. Centeo is about to launch its proprietary technology into the global life sciences sector.
The company has designed a hand-held portable thermal control unit, which allows test samples to be exposed to multiple, controlled temperatures throughout the experiment protocol, saving time and increasing the accuracy of testing. No similar product is currently on the market.
The technology has been developed over the last four years by CEO Dr Gabriela Juarez-Martinez and Dr Philipp Steinmann, CTO, and is set to transform thermal control protocols in the pharmaceutical and academic research sectors, where more than £500 million is routinely committed to the research and launch of each new drug.
Centeo’s automated equipment is currently designed for protein crystallisation but is also suitable for other markets, and the company is working on a number of further developments to extend the technology’s applications.
February 2010
Centeo Biosciences secures a further £200,000 in second round funding from existing investors - including members of TRI Cap, Highland Venture Capital, TRI Cap, Scottish Enterprise and LINC Scotland - new investors and founders.
The funding will support further production and marketing at the company, which is promoting its proprietary technology into the global life sciences sector.
The company is aiming for a further £200,000 of funding in the first half of 2010.
TRI Cap Contact: Sandra Nattrass
Number of TRI Cap Investors: 9
Centeo Contact: CEO Dr. Gabriela Juárez-Martínez
Centeo Biosciences Ltd.
Vale of Leven I.E.
Dumbarton
e: info@centeo.com
http://www.centeo.com